GPC3 and hepatocellular carcinoma: Knockdown of Glypican-3 (GPC3) inhibits the growth, stemness, and glycolytic development of HCC cells in the hypoxic microenvironment by reducing lactylation modifications, indicating that GPC3-mediated lactylation may represent a novel therapeutic direction for HCC [122].